Clinical Trial Update: Evaluation of Brimonidine Tartrate/Ketotifen Fumarate Combination for the Treatment of Allergic Conjunctivitis [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating a fixed-dose combination of brimonidine tartrate and ketotifen fumarate for allergic conjunctivitis has completed with results posted…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Allergic Conjunctivitis

Drugs mentioned

• BRIMONIDINE TARTRATE (brimonidine tartrate)
• Ketotifen Fumarate (ketotifen fumarate)

Snippet

Sponsor: Bausch & Lomb Incorporated | Conditions: Allergic Conjunctivitis | Phase 3 | Status: COMPLETED | Results posted: 2025-02-14